{"contentid": 488018, "importid": NaN, "name": "Another string to the bow in global pandemic fight", "introduction": "Positive Phase III data from East Coast, USA-based vaccine specialist Novavax could soon pave the way for another approved option against the novel coronavirus.", "content": "<p>Positive Phase III data from East Coast, USA-based vaccine specialist Novavax (Nasdaq: NVAX) could soon pave the way for another approved option against the novel coronavirus.</p>\n<p>Final efficacy numbers from a large UK-based study show the candidate was 96.4% effective against mild, moderate and severe disease caused by the original COVID-19 strain.</p>\n<p>Less encouragingly, a different set of results from a Phase IIb trial in South Africa show efficacy of 55.4% - the majority of strains in this region are of the B1.351 type.</p>\n<p>However, both studies reached the statistical bar for success, and showed 100% protection against severe disease, including all hospitalization and death.</p>\n<h2>High demand</h2>\n<p>The positive results will come as a relief for governments around the world, as demand for coronavirus vaccines outstrips supplies, including in Europe.</p>\n<p>With tensions running high, excess demand has led to international disputes, with the EU demanding earlier in the year that AstraZeneca (LSE: AZN) should tap into its UK supply chain to make up for a shortfall.</p>\n<p>More recently, the USA told EU officials that it would not permit stocks of American-made COVID-19 Vaccine AstraZeneca to be exported, despite the US FDA not yet having approved the vaccine.</p>\n<p>The Novavax jab could help alleviate the situation. The company has previously said it should be able to produce up to 150 million vaccine doses monthly by the middle of the year.</p>\n<p>Regulators in the UK, Europe and elsewhere are already reviewing data from the trials and are expected to deliver a verdict on approval in the near future.</p>\n<p>Commenting on the trial results, chief executive Stanly Erck said: \"We are very encouraged by the data showing that NVX-CoV2373 not only provided complete protection against the most severe forms of disease, but also dramatically reduced mild and moderate disease across both trials.&rdquo;</p>\n<p>Novavax expects the data to serve as the basis for submission for authorization to various regulatory agencies worldwide.</p>", "date": "2021-03-12 11:32:00", "meta_title": NaN, "meta_keywords": "vaccine, data, Novavax, Phase, positive, coronavirus, approved, disease, global, string, pandemic, fight, specialist, pave, Coast, option, East, USA-based", "meta_description": "Positive Phase III data from East Coast, USA-based vaccine specialist Novavax could soon pave the way for another approved option against the novel coronavirus.", "meta_robots": NaN, "meta_display_in_sitemap": 1, "canonical_url": NaN, "status": 3, "access_status": 0, "ignore_flexible_sampling": 0, "display_start_date": "0000-00-00 00:00:00", "display_end_date": "0000-00-00 00:00:00", "display_in_search": 1, "created": "2021-03-12 10:01:33", "updated": "2021-03-12 11:33:42", "access": NaN, "url": "https://www.thepharmaletter.com/article/another-string-to-the-bow-in-global-pandemic-fight", "description": NaN, "twitter_term": NaN, "twitter_widgetid": NaN, "key_facts": NaN, "news_snippet": NaN, "image1id": "novavax-large.png", "image2id": "novavax-small.png", "restrict_print": 0, "restrict_print_for_logged_out": 0, "box1_header": NaN, "box1_title": NaN, "box1_image1id": 0, "box1_url": NaN, "box1_introduction": NaN, "box1_position": 0, "tags": NaN, "sector_tag": "Biotechnology", "therapy area_tag": "Infectious diseases, Vaccines", "topic_tag": "Coronavirus, Drug Trial, Focus On, Research", "geography_tag": "Europe, USA", "company_tag": "Novavax", "drug_tag": "NVX-CoV2373", "market index_tag": NaN, "theme_tag": NaN, "industry sector_tag": NaN, "medical condition_tag": NaN, "industry term_tag": NaN, "organization_tag": NaN, "person_tag": NaN, "position_tag": NaN, "medical treatment_tag": NaN, "facility_tag": NaN, "technology_tag": NaN, "journalist_tag": NaN, "published medium_tag": NaN, "political event_tag": NaN, "anniversary_tag": NaN, "sports event_tag": NaN, "movie_tag": NaN, "fax number_tag": NaN, "currency pair_tag": NaN, "sports league_tag": NaN, "date_tag": NaN, "music group_tag": NaN, "phone number_tag": NaN, "t v show_tag": NaN, "t v station_tag": NaN, "entertainment award event_tag": NaN, "industry_tag": NaN, "pharmaceutical drug_tag": NaN, "topmost public parent company_tag": NaN, "content_type_name": "Article", "pubDate": "2021-03-12 11:32:00"}